NYSE American - Delayed Quote USD
IGC Pharma, Inc. (IGC)
At close: November 4 at 3:58 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.03 | -0.03 | -0.11 | -0.1 |
| Low Estimate | -0.03 | -0.03 | -0.13 | -0.12 |
| High Estimate | -0.02 | -0.02 | -0.09 | -0.09 |
| Year Ago EPS | -- | -- | -0.22 | -0.11 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 300k | 250k | 1.13M | 1.28M |
| Low Estimate | 290k | 200k | 1.06M | 1.17M |
| High Estimate | 300k | 300k | 1.2M | 1.4M |
| Year Ago Sales | -- | -- | 1.34M | 1.13M |
| Sales Growth (year/est) | -- | -- | -16.00% | 13.30% |
Earnings History
| CURRENCY IN USD | 3/31/2024 | 6/30/2024 |
|---|---|---|
| EPS Est. | -0.04 | -0.03 |
| EPS Actual | -0.4 | -0.03 |
| Difference | -0.36 | 0 |
| Surprise % | -900.00% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.03 | -0.03 | -0.11 | -0.1 |
| 7 Days Ago | -0.03 | -0.03 | -0.11 | -0.1 |
| 30 Days Ago | -0.03 | -0.03 | -0.11 | -0.1 |
| 60 Days Ago | -0.03 | -0.03 | -0.11 | -0.1 |
| 90 Days Ago | -0.03 | -0.03 | -0.1 | -0.1 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | IGC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 5.20% |
| Next Qtr. | -- | -- | -- | 11.60% |
| Current Year | 50.00% | -- | -- | 2.10% |
| Next Year | 9.10% | -- | -- | 12.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.04% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Ascendiant Capital: Buy to Buy | 9/3/2024 |
| Maintains | Ascendiant Capital: Buy to Buy | 7/29/2024 |
| Initiated | Alliance Global Partners: Buy | 7/17/2024 |
| Reiterates | Ascendiant Capital: Buy to Buy | 6/21/2024 |
Related Tickers
ENVB Enveric Biosciences, Inc.
0.4640
-5.63%
ARDS Aridis Pharmaceuticals, Inc.
0.0002
0.00%
XBIO Xenetic Biosciences, Inc.
3.6629
-12.79%
BRNS Barinthus Biotherapeutics plc
1.4466
-0.23%
PHRRF PharmaTher Holdings Ltd.
0.1730
+0.58%
GYRE Gyre Therapeutics, Inc.
14.74
+1.87%
IMRX Immuneering Corporation
1.8600
-0.53%
TRVI Trevi Therapeutics, Inc.
3.0400
+1.00%
OCEA Ocean Biomedical, Inc.
0.8999
+1.16%
IMNN Imunon, Inc.
0.9799
+3.15%